Aspira Pathlab

Market Cap: Micro Cap
Industry: Healthcare Services
ISIN: INE500C01017
NSEID:
BSEID: 540788

INR

64.91

-0.12 (-0.18%)

BSENSE

Dec 18

BSE+NSE Vol: 325

{
  "main_header": {
    "sid": 1002885,
    "name": "Aspira Pathlab",
    "stock_name": "Aspira Pathlab",
    "full_name": "Aspira Pathlab & Diagnostics Ltd",
    "name_url": "stocks-analysis/aspira-pathlab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "64.91",
    "chg": -0.12,
    "chgp": "-0.18%",
    "dir": -1,
    "prev_price": "65.03",
    "mcapval": "67.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540788,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE500C01017",
    "curr_date": "Dec 18",
    "curr_time": "",
    "bse_nse_vol": 325,
    "exc_status": "Active",
    "traded_date": "Dec 18, 2025",
    "traded_date_str": "2025 12 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aspira-pathlab-1002885-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Financial and Technical Developments",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-upgraded-to-hold-on-improved-technicals-and-strong-financials-3759706",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3759706.png",
        "date": "2025-12-16 08:48:05",
        "description": "Aspira Pathlab & Diagnostics has experienced a notable revision in market assessment following a comprehensive review of its quality, valuation, financial trends, and technical indicators. This shift reflects evolving dynamics in the healthcare services sector and the company’s recent performance metrics."
      },
      {
        "title": "Why is Aspira Pathlab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-aspira-pathlab-fallingrising-3754480",
        "imagepath": "",
        "date": "2025-12-10 00:53:21",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>On 09 December, Aspira Pathlab’s stock demonstrated strong intraday momentum, reaching a high of ₹72, representing a 9.16% increase during the session. The stock outperformed its sector by 7.89%, signalling investor confidence in the company’s prospects. Notably, the share price is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained upward trend in technical terms.</p>\n<p>Despite a decline in delivery volume on 08 December by 75.43% compared to the five-day average, the stock maintained liquidity sufficient for sizeable trades, suggesting that the price rise is supported by quality demand rather than speculative spikes.</p>\n<div class=\"promo-strategy-box\">\n<p..."
      },
      {
        "title": "Aspira Pathlab & Diagnostics: Analytical Revisions Reflect Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-downgraded-to-sell-amid-mixed-technicals-and-valuation-concerns-3753106",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3753106.png",
        "date": "2025-12-09 09:04:05",
        "description": "Aspira Pathlab & Diagnostics has recently undergone a revision in its market evaluation, reflecting a nuanced shift in analytical perspectives across key parameters including quality, valuation, financial trends, and technical indicators. This article examines the factors influencing these changes and their implications for investors in the healthcare services sector."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Hits Upper Circuit Amidst Unprecedented Buying Interest",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-hits-upper-circuit-amidst-unprecedented-buying-frenzy-3741016",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_only_buyers_3741016.png",
        "date": "2025-12-02 09:36:27",
        "description": "Aspira Pathlab & Diagnostics has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. The stock’s performance today stands out sharply against the broader market, signalling robust investor enthusiasm and the potential for a sustained multi-day circuit scenario."
      },
      {
        "title": "Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-upgraded-to-hold-on-improved-technicals-and-strong-financials-3740762",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3740762.png",
        "date": "2025-12-02 08:59:32",
        "description": "Aspira Pathlab & Diagnostics has experienced a revision in its market assessment, reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent analytical perspective shifts for the healthcare services company, highlighting its financial performance, market behaviour, and technical signals."
      },
      {
        "title": "How has been the historical performance of Aspira Pathlab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-aspira-pathlab-3739372",
        "imagepath": "",
        "date": "2025-12-01 23:33:21",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue Growth and Profitability Improvement</strong></p>\n<p>In the fiscal year ending March 2025, Aspira Pathlab reported consolidated net sales of ₹22.00 crore, marking a significant increase from ₹13.20 crore in the previous year. This growth of approximately 66.7% underscores the company’s expanding market presence and operational scale. Despite no other operating income reported in either year, the total operating income mirrored net sales, reflecting a focused revenue stream.</p>\n<p>Cost management remained a critical factor in the company’s improved profitability. Raw material costs rose moderately from ₹2.62 crore to ₹3.70 crore, while employee expenses increased from ₹6.20 crore to ₹7.33 crore, consistent with the company’s growth trajectory. Selling and distribution expenses remain..."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Sees Unprecedented Buying Interest, Edging Towards Multi-Day Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-hits-upper-circuit-amid-unprecedented-buying-interest-3738838",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_only_buyers_3738838.png",
        "date": "2025-12-01 14:50:36",
        "description": "Aspira Pathlab & Diagnostics Ltd has captured the market’s attention with extraordinary buying momentum, registering a 4.98% gain today while the broader Sensex slipped marginally by 0.07%. The stock’s unique position of having only buy orders in the queue signals a potential multi-day upper circuit scenario, underscoring robust investor demand in the healthcare services sector."
      },
      {
        "title": "Why is Aspira Pathlab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-aspira-pathlab-fallingrising-3716530",
        "imagepath": "",
        "date": "2025-11-19 23:54:24",
        "description": "As of 19-Nov, Aspira Pathlab & Diagnostics Ltd is experiencing a price increase, with its current price at Rs 64.20, reflecting a rise of Rs 1.82 or 2.92%. The stock has shown strong performance today, outperforming its sector by 2.26% and achieving a consecutive gain over the last two days, with a total return of 7% during this period. Additionally, the stock reached an intraday high of Rs 65.49, indicating positive momentum. In terms of returns, the stock has increased by 8.72% over the past week, although it has seen a decline of 4.01% over the past month. Notably, the stock's delivery volume has surged by 438.18% compared to the 5-day average, suggesting rising investor participation. There is no information available regarding positive or negative factors that could influence the stock's movement.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has gained 0.85% over the past week,..."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Hits Upper Circuit with Only Buy Orders: A Multi-Day Rally in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-hits-upper-circuit-amidst-unprecedented-buying-interest-3715506",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AspiraPathlabDi_only_buyers_3715506.png",
        "date": "2025-11-19 14:21:07",
        "description": "Aspira Pathlab & Diagnostics Ltd has witnessed extraordinary buying interest on 19 Nov 2025, hitting the upper circuit with exclusively buy orders in the queue. This rare market phenomenon signals robust demand and the potential for a sustained multi-day circuit scenario, underscoring the stock’s strong momentum in the healthcare services sector."
      }
    ],
    "total": 6123,
    "sid": "1002885",
    "stock_news_url": "https://www.marketsmojo.com/news/aspira-pathlab-diagnostics-1002885"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "13-Nov-2025",
      "details": "Newspaper Publication of Standalone Financial Results for the quarter and half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On November 12 2025",
      "datetime": "12-Nov-2025",
      "details": "Outcome of Board Meeting held on November 12 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
      "datetime": "12-Nov-2025",
      "details": "Appointment of Mrs. Kiran Raghavendra Awsathi (DIN:09066721) as Additional Independent Director subject to the members approval.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Financial and Technical Developments

2025-12-16 08:48:05

Aspira Pathlab & Diagnostics has experienced a notable revision in market assessment following a comprehensive review of its quality, valuation, financial trends, and technical indicators. This shift reflects evolving dynamics in the healthcare services sector and the company’s recent performance metrics.

Why is Aspira Pathlab falling/rising?

2025-12-10 00:53:21

Recent Price Movement and Market Context

On 09 December, Aspira Pathlab’s stock demonstrated strong intraday momentum, reaching a high of ₹72, representing a 9.16% increase during the session. The stock outperformed its sector by 7.89%, signalling investor confidence in the company’s prospects. Notably, the share price is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained upward trend in technical terms.

Despite a decline in delivery volume on 08 December by 75.43% compared to the five-day average, the stock maintained liquidity sufficient for sizeable trades, suggesting that the price rise is supported by quality demand rather than speculative spikes.

Aspira Pathlab & Diagnostics: Analytical Revisions Reflect Mixed Market Signals

2025-12-09 09:04:05

Aspira Pathlab & Diagnostics has recently undergone a revision in its market evaluation, reflecting a nuanced shift in analytical perspectives across key parameters including quality, valuation, financial trends, and technical indicators. This article examines the factors influencing these changes and their implications for investors in the healthcare services sector.

Aspira Pathlab & Diagnostics Hits Upper Circuit Amidst Unprecedented Buying Interest

2025-12-02 09:36:27

Aspira Pathlab & Diagnostics has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. The stock’s performance today stands out sharply against the broader market, signalling robust investor enthusiasm and the potential for a sustained multi-day circuit scenario.

Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Mixed Market Signals

2025-12-02 08:59:32

Aspira Pathlab & Diagnostics has experienced a revision in its market assessment, reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent analytical perspective shifts for the healthcare services company, highlighting its financial performance, market behaviour, and technical signals.

How has been the historical performance of Aspira Pathlab?

2025-12-01 23:33:21

Revenue Growth and Profitability Improvement

In the fiscal year ending March 2025, Aspira Pathlab reported consolidated net sales of ₹22.00 crore, marking a significant increase from ₹13.20 crore in the previous year. This growth of approximately 66.7% underscores the company’s expanding market presence and operational scale. Despite no other operating income reported in either year, the total operating income mirrored net sales, reflecting a focused revenue stream.

Cost management remained a critical factor in the company’s improved profitability. Raw material costs rose moderately from ₹2.62 crore to ₹3.70 crore, while employee expenses increased from ₹6.20 crore to ₹7.33 crore, consistent with the company’s growth trajectory. Selling and distribution expenses remain...

Aspira Pathlab & Diagnostics Sees Unprecedented Buying Interest, Edging Towards Multi-Day Upper Circuit

2025-12-01 14:50:36

Aspira Pathlab & Diagnostics Ltd has captured the market’s attention with extraordinary buying momentum, registering a 4.98% gain today while the broader Sensex slipped marginally by 0.07%. The stock’s unique position of having only buy orders in the queue signals a potential multi-day upper circuit scenario, underscoring robust investor demand in the healthcare services sector.

Why is Aspira Pathlab falling/rising?

2025-11-19 23:54:24

As of 19-Nov, Aspira Pathlab & Diagnostics Ltd is experiencing a price increase, with its current price at Rs 64.20, reflecting a rise of Rs 1.82 or 2.92%. The stock has shown strong performance today, outperforming its sector by 2.26% and achieving a consecutive gain over the last two days, with a total return of 7% during this period. Additionally, the stock reached an intraday high of Rs 65.49, indicating positive momentum. In terms of returns, the stock has increased by 8.72% over the past week, although it has seen a decline of 4.01% over the past month. Notably, the stock's delivery volume has surged by 438.18% compared to the 5-day average, suggesting rising investor participation. There is no information available regarding positive or negative factors that could influence the stock's movement. Broader Market Context: In comparison to the benchmark Sensex, which has gained 0.85% over the past week,...

Aspira Pathlab & Diagnostics Hits Upper Circuit with Only Buy Orders: A Multi-Day Rally in Sight

2025-11-19 14:21:07

Aspira Pathlab & Diagnostics Ltd has witnessed extraordinary buying interest on 19 Nov 2025, hitting the upper circuit with exclusively buy orders in the queue. This rare market phenomenon signals robust demand and the potential for a sustained multi-day circuit scenario, underscoring the stock’s strong momentum in the healthcare services sector.